Reports Q2 revenue $798.6M, consensus $803.65M. “Our Q2 yet again produced record-setting results driven by the strength of our foundational commercial business,” said Martine Rothblatt, Chairperson and CEO of United Therapeutics (UTHR). “We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth, starting with data from the TETON 2 study of nebulized treprostinil in idiopathic pulmonary fibrosis expected in September that could fundamentally improve options for patients with this progressive, deadly disease with few treatments available.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Notable companies reporting before tomorrow’s open
- Bleecker Street Research short United Therapeutics, long Liquidia
- United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for Pulmonary Fibrosis
- United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer?
- United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment